As of November 6, 2026, Cingulate Inc. is a publicly traded company (Nasdaq: CING). The largest holder reporting an active stake on Schedule 13D is Falcon Creek Capital Advisor LLC, at 28.5%. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13D/A, March 26, 2026).
Is this your company?
About to sign with, pay or invest in Cingulate Inc.? See the free Snapshot first.
Free to see. No signup.
Is Cingulate Inc. a real, registered company?
- Cingulate Inc. files with the SEC under CIK 1862150 (its SEC filings).
- Its shares are listed under the ticker CING on Nasdaq (also CINGW) (SEC company record).
- Incorporated in Delaware; business address in Kansas City, Kansas, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Cingulate Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Jeff Hargroves, Director (Form 8-K filed 2026-07-14). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Falcon Creek Capital Advisor LLC (filed 2026-03-26).
Who are Cingulate Inc.'s owners and officers?
Cingulate Inc.: incorporated in Delaware; business address in Kansas City, Kansas; industry Pharmaceutical Preparations (Form D, 2026-07-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-03-26 | Falcon Creek Capital Advisor LLC | 28.5% |
| Schedule 13D, 2026-02-09 | Falcon Creek Capital Advisor LLC | 19.9% |
Questions about who owns Cingulate Inc.
Who owns Cingulate Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Cingulate Inc.: Falcon Creek Capital Advisor LLC (28.5%, Schedule 13D/A, filed 2026-03-26).
When did Falcon Creek Capital Advisor LLC buy into Cingulate Inc.?
The filings give report dates, not purchase dates. The earliest filing from Falcon Creek Capital Advisor LLC on this page is the Schedule 13D, filed 2026-02-09, reporting 19.9%; its latest, Schedule 13D/A filed 2026-03-26, reports 28.5%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Cingulate Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Cingulate Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cingulate Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-07-14 | Jeff Hargroves | Director | appointed | |
| Form 8-K, 2026-05-19 | Jeff Hargroves | Director | appointed |
Which insiders own Cingulate Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 117,541 shares (0.81% of shares outstanding), 92 held directly and 117,449 indirectly (Form 4, 2026-02-10).
- , a director: 97,468 shares (0.67% of shares outstanding), held indirectly through By Hargroves Family Investments, LLC (Form 4, 2026-06-08).
- , the chief executive and a director: 14,251 shares (0.10% of shares outstanding), 4,076 held directly and 10,175 indirectly (Form 4, 2026-03-11).
- , the chief financial officer and executive vice president: 13,961 shares (0.10% of shares outstanding) (Form 4, 2026-03-11).
- , the executive vice president and chief medical officer: 8,157 shares (0.06% of shares outstanding) (Form 4, 2026-03-11).
Shares outstanding: 14,541,826 as of 2026-08-12, from the company's latest SEC cover page.
How much has Cingulate Inc. raised?
Latest IPO step: Cingulate Inc. amended its IPO registration (S-1/A, 2025-07-25).
IPO filings: S-1/A, 2025-07-25, S-1, 2025-07-22, S-1/A, 2024-10-07, S-1/A, 2024-10-03, S-1, 2024-09-27.
Keep reading
More on Cingulate Inc. and the records around it.
Cingulate Inc. elsewhere on the record
- Leadership changes Jul 2026
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/cingulate